New vaccine adoption: Qualitative study of national decision-making processes in seven low- and middle-income countries

Health Policy and Planning

Volumn 27, Issue SUPPL.2, 2012, Pages

  Burchett, H E D ^a   Mounier Jack, S ^a   Griffiths, U K ^a   Biellik, R ^b   Ongolo Zogo, P ^b   Chavez, E ^b   Sarma, H ^d   Uddin, J ^d   Konate, M ^c   Kitaw, Y ^c   Molla, M ^d   Wakasiaka, S ^e   Gilson, L ^a,f   Mills, A ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b YAOUNDÉ CENTRAL HOSPITAL   (Cameroon)

^c ICDDR B   (Bangladesh)

^d ADDIS ABABA UNIVERSITY   (Ethiopia)

^e UNIVERSITY OF NAIROBI   (Kenya)

^f UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Immunization; policy process; qualitative

Indexed keywords

VACCINE;

ARTICLE; BANGLADESH; CAMEROON; DEVELOPING COUNTRY; ECONOMICS; ETHIOPIA; GUATEMALA; HEALTH CARE PLANNING; HUMAN; KENYA; MALI; MANAGEMENT; ORGANIZATION; ORGANIZATION AND MANAGEMENT; POLITICS; PREVENTIVE HEALTH SERVICE; SOUTH AFRICA;

BANGLADESH; CAMEROON; DECISION MAKING, ORGANIZATIONAL; DEVELOPING COUNTRIES; ETHIOPIA; GUATEMALA; HEALTH PRIORITIES; HUMANS; IMMUNIZATION PROGRAMS; KENYA; MALI; POLICY MAKING; POLITICS; SOUTH AFRICA; VACCINES;

EID: 84860180538     PISSN: 02681080     EISSN: 14602237     Source Type: Journal    
DOI: 10.1093/heapol/czs035     Document Type: Article

References (48)

1. Acosta CJ, Galindo CM, Ochiai RL et al. 2004. The role of epidemiology in the introduction of Vi polysaccharide typhoid fever vaccines in Asia. (Special Issue on a New Research Agenda for Introducing New Vaccines in Developing Countries: Translational Research). Journal of Health, Population and Nutrition 22: 240-5.
2. Andrus JK, Jauregui B, De Oliveira LH, Matus CR. 2011. Challenges to building capacity for evidence-based new vaccine policy in developing countries. Health Affairs 30: 1104-12.
3. Andrus JK, Toscano CM, Lewis M et al. 2007. A model for enhancing evidence-based capacity to make informed policy decisions on the introduction of new vaccines in the Americas: PAHO's ProVac initiative. Public Health Reports 122: 811-6.
4. Brooks A, Cutts FT, Justice J, Walt G. 1999. Policy study of factors influencing the adoption of new and underutilized vaccines in developing countries. San Francisco and London: University of California and London School of Hygiene & Tropical Medicine.
5. Bryson M, Duclos P, Jolly A, Bryson J. 2010. A systematic review of national immunization policy making procesess. Vaccine 28: S6-12.
6. Burchett HED. 2010. Perceptions of the usefulness of public health research for policy in Ghana. PhD, University of London.
7. Burchett HED, Mounier-Jack S, Griffiths UK, Mills A. 2012. National decision-making on adopting new vaccines: a systematic review. Health Policy and Planning 27(Suppl. 2):ii62-ii76.
8. Central Statistical Agency Ethiopia. 2009. Statistical Abstract Ethiopia. Addis Ababa: CSA.
9. Cunliffe N, Nakagomi O. 2007. Introduction of rotavirus vaccines in developing countries: remaining challenges. Annals of Tropical Paediatrics 27: 157-67.
10. DeRoeck D. 2004. The importance of engaging policy-makers at the outset to guide research on and introduction of vaccines: the use of policy-maker surveys. (Special Issue on a New Research Agenda for Introducing New Vaccines in Developing Countries: Translational Research). Journal of Health, Population and Nutrition 22: 322-30.
11. DeRoeck D, Clemens JD, Nyamete A, Mahoney RT. 2005. Policymakers' views regarding the introduction of new-generation vaccines against typhoid fever, shigellosis and cholera in Asia. Vaccine 23: 2762-74.
12. DeRoeck D, Deen J, Clemens JD. 2003. Policymakers' views on dengue fever/dengue haemorrhagic fever and the need for dengue vaccines in four southeast Asian countries. Vaccine 22: 121-9.
13. Druce N, Atim C, Grace C et al. 2006. Evidence-informed decision making processes for new vaccines and other technologies: strengthening capacity at country level. London: HLSP.
14. GAVI Alliance. 2011. Eligible countries. Online at: http://www. gavialliance.org/support/who/eligible/index.php, accessed 13 July 2011.
15. Gordon S, Jones A, Wecker J. 2012. Introducing multiple vaccines in low- and middle-income countries: issues, opportunities and challenges. Health Policy and Planning 27(Suppl. 2):ii17-ii26.
16. Haas M, Ashton T, Blum K et al. 2009. Drugs, sex, money and power: an HPV vaccine case study. Health Policy 92: 288-95.
17. Hajjeh RA, Privor-Dumm L, Edmond K et al. 2010. Supporting new vaccine introduction decisions: lessons learned from the Hib Initiative experience. Vaccine 28: 7123-9.
18. Institut National de la Statistique Republique du Mali. 2011. Indicateurs recents. Online at: http://instat.gov.ml/, accessed 13 July 2011.
19. Jauregui B, Sinha A, Clark AD et al. 2011. Strengthening the technical capacity at country-level to make informed policy decisions on new vaccine introduction: lessons learned by PAHO's ProVac Initiative. Vaccine 29: 1099-106.
20. Lairumbi GM, Molyneux S, Snow RW et al. 2008. Promoting the social value of research in Kenya: examining the practical aspects of collaborative partnerships using an ethical framework. Social Science & Medicine 67: 734-47.
21. Levine OS. 2004. GAVI's PneumoADIP: Accelerating the prevention of pneumococcal disease by vaccination. Presentation for University of Bergen, Centre for International Health, September 20-21, 2004.
22. Levine OS, Bloom DE, Cherian T et al. 2011. The future of immunisation policy, implementation, and financing. The Lancet 378: 439-48.
23. Levine OS, Hajjeh R, Wecker J et al. 2010. A policy framework for accelerating adoption of new vaccines. Human Vaccines 6: 1021-4.
24. Lin V. 2003. Competing rationalities: evidence-based health policy? In: Lin V, Gibson B (eds). Evidence-Based Health Policy: Problems and Possibilities. Oxford: Oxford University Press.
25. Lydon P, Levine R, Makinen M et al. 2008. Introducing new vaccines in the poorest countries: what did we learn from the GAVI experience with financial sustainability? Vaccine 26: 6706-16.
26. Mahmoud A. 2011. A global road map is needed for vaccine research, development and deployment. Health Affairs 6: 1034-41.
27. McQuestion M, Gnawali D, Kamara C et al. 2011. Creating sustainable financing and support for immunization programs in fifteen developing countries. Health Affairs 30: 1134-40.
28. Moszynski P. 2011. London vaccination summit is "milestone in global health". British Medical Journal 342: d3766.
29. Moxon ER, Das P, Greenwood B et al. 2011. A call to action for the new decade of vaccines. The Lancet 378: 298-302.
30. Moxon ER, Siegrist C-A. 2011. The next decade of vaccines: societal and scientific challenges. The Lancet 378: 348-59.
31. Munira SL, Fritzen SA. 2007. What influences government adoption of vaccines in developing countries? A policy process analysis. Social Science & Medicine 65: 1751-64.
32. Piso B, Wild C. 2009. Decision support in vaccination policies. Vaccine 27: 5923-8.
33. Program For Appropriate Technology in Health (PATH), US Centers for Disease Control and Prevention & World Health Organization. 2003. Accelerated Development and Introduction Plan (ADIP) for Rotavirus Vaccines: A Final Revised Proposal to GAVI. Seattle, WA: PATH.
34. Ritchie J, Spencer L. 1994. Qualitative data analysis for applied policy research. In: Bryman A, Burgess RG (eds). Analyzing Qualitative Data. London: Routledge.
35. Senouci K, Blau H, Nyambat B et al. 2010. The Supporting Independent Immunization and Vaccine Advisory Committees (SIVAC) Initiative: a country-driven, multi-partner program to support evidence-based decision making. Vaccine 28: A26-30.
36. Shearer JC, Stack ML, Richmond MR et al. 2010. accelerating policy decisions to adopt Haemophilus influenzae type b vaccine: a global, multivariable analysis. PLoS Medicine 7: e1000249.
37. Shiffman J, Smith S. 2007. Generation of political priority of global health initiatives: a framework and case study of maternal mortality. The Lancet 370: 1370-9.
38. Simpson E, Wittet S, Bonilla J et al. 2007. Use of formative research in developing a knowledge translation approach to rotavirus vaccine introduction in developing countries. BMC Public Health 7: 281.
39. Umea University. 2011. Open code. Umea, Sweden: Umea University. Online at: http://www.phmed.umu.se/english/divisions/epidemiology/research/open-code/, accessed 8 March 2011.
40. Weber W. 2004. Redefining GAVI Hib Strategy: The country consultation process. Trip report: October 9-16, 2004. Euro Health Group Consultants, Liverpool Associates in Tropical Health, UK.
41. Wenger JD, Difabio J, Landaverde JM, Levine OS, Gaafar T. 1999. Introduction of Hib conjugate vaccines in the non-industrialized world: experience in four 'newly adopting' countries. Vaccine 18: 736-42.
42. Widdowson MA, Steele D, Vojdani J, Wecker J, Parashar U. 2009. Global rotavirus surveillance: determining the need and measuring the impact of rotavirus vaccines. Journal of Infectious Diseases 200(Suppl. 1):S1-8.
43. Woelk G, Daniels K, Cliff J et al. 2009. Translating research into policy: lessons learned from eclampsia treatment and malaria control in three southern African countries. Health Research Policy and Systems 7: 31.
44. World Bank. 2011. Data: Indicators. Online at: http://data.worldbank.org/ indicator, accessed 1 July 2011.
45. World Health Organization. 2008. Progress Introducing Haemophilus influenzae type b vaccine in low-income countries. Weekly Epidemiological Record 83: 62-7.
46. World Health Organization. 2011a. WHO/UNICEF estimates of national immunization coverage. Online at: http://www.who.int/immunization-monitoring/ routine/immunization-coverage/en/index4.html, accessed 13th July 2011.
47. World Health Organization. 2011b. WHO Vaccine Preventable Diseases Monitoring System: 2011 Global Summary. Geneva: WHO.
48. Zuber PL, El-Ziq I, Kaddar M et al. 2011. Sustaining GAVI-supported vaccine introductions in resource-poor countries. Vaccine 29: 3149-54.